Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia

被引：6
|
作者：
Kinjyo, Ichiko [1 ]
Matlawska-Wasowska, Ksenia [2 ,3 ]
Chen, Xiaoru [4 ]
Monks, Noel R. [5 ]
Burke, Patricia [4 ]
Winter, Stuart S. [2 ,3 ]
Wilson, Bridget S. [1 ,2 ]
机构：
[1] Univ New Mexico, Dept Pathol, Hlth Sci Ctr, Albuquerque, NM 87131 USA
[2] Univ New Mexico, Ctr Canc, Hlth Sci Ctr, Albuquerque, NM 87131 USA
[3] Univ New Mexico, Dept Pediat, Hlth Sci Ctr, Div Hematol Oncol, Albuquerque, NM 87131 USA
[4] MedImmune, Translat Med Oncol, Gaithersburg, MD USA
[5] MedImmune, Oncol Res, Gaithersburg, MD USA
来源：
PEDIATRIC BLOOD & CANCER | 2017年 / 64卷 / 11期
关键词：
acute lymphoblastic leukemia; immunotherapy; HEMATOLOGIC MALIGNANCIES; PSEUDOMONAS EXOTOXIN; IMMUNOTOXIN; CAT-8015; TRIAL; HA22; CD22;
D O I：
10.1002/pbc.26604
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Moxetumomab pasudotox is a second-generation recombinant immunotoxin against CD22 on B-cell lineages. Antileukemic activity has been demonstrated in children with chemotherapy-refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL), with variable responses. Here, we report in vitro and in vivo evaluation of moxetumomab pasudotox treatment of human cell lines and patient-derived cells as a preliminary study to understand characteristics of sensitivity to treatment. Binding, internalization, and apoptosis were evaluated using fluorescently tagged moxetumomab pasudotox. Studies in NOD-scid IL2Rg(null) mice showed a modest survival benefit in mice engrafted with 697 cells but not in NALM6 or the two patient-derived xenograft models.
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Advances in B-cell Precursor Acute Lymphoblastic Leukemia Genomics
    Schwab, Claire
    Harrison, Christine J.
    HEMASPHERE, 2018, 2 (04):
  • [32] Intraocular Invasion of B-Cell Precursor Acute Lymphoblastic Leukemia
    Torii, Daiki
    Nino, Nanako
    Masuda, Chika
    Nakatani, Naoko
    Tamura, Akihiro
    Yamamoto, Nobuyuki
    Ueda, Kaori
    Imai, Hisanori
    Nishimura, Noriyuki
    Nozu, Kandai
    PEDIATRIC BLOOD & CANCER, 2021, 68
  • [33] Anti-CD19/CD22 Dual CAR-T Therapy for Refractory and Relapsed B-Cell Acute Lymphoblastic Leukemia
    Yang, Junfang
    Jiang, Pengfei
    Zhang, Xian
    Zhu, Xiaobin
    Dong, Qi
    He, Jiaping
    Lin, Nanjing
    Wang, Zhenguang
    Cai, Songbai
    Ye, Xun
    Su, Yunchao
    Li, Wenqian
    Li, Jingjing
    Yu, Ziyao
    He, Jiujiang
    Xu, Li
    Song, Dan
    Cao, Wei
    Lu, Peihua
    BLOOD, 2019, 134
  • [34] Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia
    Phely, Laurent
    Hensen, Luca
    Faul, Christoph
    Ruff, Christer Alexander
    Schneider, Dina
    Bethge, Wolfgang Andreas
    Lengerke, Claudia
    JAMA ONCOLOGY, 2024, 10 (06) : 821 - 824
  • [35] Targeted combination treatment for B-cell acute lymphoblastic leukemia
    Kane, Shriya
    Ding, Yali
    Gowda, Chandrika
    Payne, Jonathon Lee
    Iyer, Soumya
    Dhanyamraju, Pavan K.
    Song, Chunhua
    Desai, Dhimant
    Sharma, Arati
    Payne, Kimberly J.
    Dovat, Sinisa
    CANCER RESEARCH, 2020, 80 (16)
  • [36] Prognostic relevance of CD20 in adult B-cell precursor acute lymphoblastic leukemia
    Chang, Hong
    Jiang, Allan
    Brandwein, Joseph
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (06): : 1040 - 1042
  • [37] Evidence of CD19-leukemic cells in B-cell precursor acute lymphoblastic leukemia
    He, H.
    Manta, L.
    Saeed, B.
    Barth-Miesala, K.
    Eckstein, V
    Trumpp, A.
    Brueggemann, M.
    Jauch, A.
    Ho, A. D.
    Lutz, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 52 - 52
  • [38] PHARMACOKINETICS OF MOXETUMOMAB PASUDOTOX, AN INVESTIGATIONAL IMMUNOTOXIN TARGETING CD22, IN PATIENTS WITH RELAPSED OR REFRACTORY HAIRY CELL LEUKEMIA
    Wang, B.
    Chang, L.
    Kreitman, R. J.
    Ibrahim, R.
    Goswami, T.
    Pastan, I.
    Liang, M.
    Roskos, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S6 - S6
  • [39] CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults
    Lanza, Francesco
    Maffini, Enrico
    Rondoni, Michela
    Massari, Evita
    Faini, Angelo Corso
    Malavasi, Fabio
    CANCERS, 2020, 12 (02)
  • [40] CD38 Is a Functional Partner of CD9 in B-Cell Precursor Acute Lymphoblastic Leukemia
    Chung, Po Yee
    Chan, Kathy Yuen Yee
    Zhang, Chi
    Xu, Yaqun
    Ng, Wing Hei
    Li, Chi Kong
    Leung, Kam Tong
    BLOOD, 2023, 142
12345